Expression of MUM1, CD30, CD15 and CD20 by neoplastic cells of Lymphomas

Abstract

In a descriptive retrospective study aiming to detect MUM1, CD30, CD15 and CD20 expression among lymphoma patients, immunohistochemistry was used. Thirty formalin fixed paraffin embedded blocks specimens (FFPB) were prepared for this study. Sections were cut by rotary microtome then stained by immunohistochemical method (new indirect method). The ages of the involved patients ranged between one year to75 years with mean age 28 (�23.3) years. Most of the patients were aggregating at age older than 41 years representing 18 (60%) and the remaining 12 (40%) were younger than 41 years. Twenty (66.7%) of the patients were males and 10 (33.3%) were females. Histopathological diagnosis of the samples revealed diffuse large B-cell non Hodgkin�s lymphoma�s (NHL) in 18 (60%) patients, five (16.7) patients were mantle NHL and the remaining 7 (23.3%) patients were classical Hodgkin�s lymphoma�s (HL). MUM1 showed positive expression in 15 (50%) patients, and negative in 15 (50%) patients The relation between histopathological diagnosis and MUM1 expression showed 10 (66.7%) positive patients and 8 (53.3%) negative patients among diffuse large B-cell NHL. Five (33.3%) positive patients and 2 (13.3%) negative patients were classical HL, five (33.3%) has no reaction with MUM1 protein represented as mantle cell NHL with statistical significance (P value < 0.05). Among the study subjects CD30 and CD15 were positive in 7 (23.3%) patients, and negative in 23 (76.7%) patients. CD20 was positive in 23 (76.7%) patients, and negative in 7 (23.3%) patients. CD20 status showed positive expression in 23(76.6%) patients and negative in 7 (23.3%), with statistical significance (P value < 0.05). It is conclude that MUM1 receptor, CD30, CD15 and CD20 are associated with lymphomas type